Clinical trials and trial design

Current and recent clinical trials are presented in this session which includes their results and an explanation of the methods that they used to conduct the trial as well as the methods used to analyse the results. It is important to share this information so that future trials can be designed to be better and more robust.

The highlight of this session was the results found from a recent Phase 2 clinical trial of a drug called KNS-760704, developed by a pharmaceutical company called Knopp Neurosciences Inc.

The two-part Phase 2 trial found that KNS-760704 was safe and well-tolerated in people with ALS (the most common form of MND) when taken for up to nine months. This means that the trial drug was tested in people with ALS for nine months and therefore the continued safety of this drug will need to be studied in future clinical trials. The trial results also showed trends suggesting the potential for reducing the rate of decline in the functional capability of patients, for example, how far people can walk unaided, lifting objects, dexterity in eating; and survival. They are now planning a larger Phase 3 clinical trial to test the effectiveness of the drug in people with ALS.

We have issued a press release regarding this clinical trial so for more information, please visit: http://www.mndassociation.org/news_and_events/our_news/kns760704.html